Hhs

FDA's early-stage clinical trial program, a mysterious single patient gets retatrutide access, and more health news from Morning Rounds

• The Trump administration announced a multi-pronged initiative on Monday aimed at strengthening the early clinical trial ecosystem within the United States. • As part of this effort, the FDA will reconsider Regenxbio’s gene therapy designed to treat Hunter syndrome, a rare pediatric disease. • This move represents a reversal of previous regulatory rejections, signaling a shift in how the agency evaluates certain high-stakes therapies.

• The U.S. Department of Health and Human Services (HHS) and the FDA have launched an "unprecedented" initiative to restore American leadership in clinical trials and counter competition from China. • A key component of the plan is an expedited investigational new drug pilot program designed to reduce early trial timelines by as much as 12 months. • Health Secretary Robert F. Califf stated the effort aims to reverse the trend of clinical research moving overseas by making the U.S. the premier location for medicine development.

• The U.S. Department of Health and Human Services (HHS) has launched a coordinated, department-wide initiative to restore American leadership in clinical research. • The ONC is working to integrate clinical trial notifications into electronic health records to connect eligible patients with research opportunities during routine care. • ARPA-H is implementing modernization programs, including THRIVE and CATALYST, which utilize AI and machine learning to optimize dosing and predict safety before patient enrollment.

• A proposed White House Office of Management and Budget (OMB) rule threatens research by using PEPFAR as a justification to increase political oversight of federal grantmaking. • Vaccine development is accelerating in response to the growing Ebola Bundibugyo outbreak to mitigate the spread of the virus. • The US Secretary of State is facing questioning from multiple Congressional committees regarding the future and strategic direction of PEPFAR.

Serious side effects from vaccines were rare, scientists found in studies funded by US taxpayer moneyThe US Food and Drug Administration has blocked the publication of several studies that found Covid-19 and shingles vaccines to be safe, according to a spokesperson from the Department of Health and Human Services.Agency scientists conducted the studies by analyzing millions of patient records and found that serious side effects from the vaccines were rare, the spokesperson confirmed. The studies – funded by taxpayer money and costing several million dollars – included research examining the safety of Covid-19 vaccines in 2023 and 2024. Continue reading...

• The Trump administration's Department of Health and Human Services notified hospitals and nursing homes on May 4, 2026, to prioritize 'real food' over sugary drinks and dietary supplements in patient meals. • The policy shift faced immediate backlash from healthcare providers concerned about implementation and patient preferences. • This agenda aims to combat diet-related diseases amid rising obesity rates, potentially affecting millions of inpatients annually.